Official reprint from UpToDate® www.uptodate.com
©2012 UpToDate®
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use (click here) ©2012 UpToDate, Inc.
Evaluation and management of aromatase inhibitor-induced bone loss
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Mar 2012. | This topic last updated: Oct 20, 2011.

INTRODUCTION — Aromatase inhibitors (AIs) are an important component of adjuvant endocrine therapy in postmenopausal women with estrogen receptor positive breast cancer. AIs inhibit the cytochrome P450 CYP-19 enzyme responsible for the peripheral conversion of androgens to estrogens [1,2]. Treatment with AIs, therefore, results in bone loss due to estrogen deficiency [3]. As more women are exposed to AIs, it is important to understand their adverse effects on the skeleton. The evaluation and management of bone loss associated with the use of AIs are reviewed here. The role of AIs as adjuvant therapy for breast cancer is discussed elsewhere. (See "Adjuvant endocrine therapy for postmenopausal women with early stage breast cancer".)

ESTROGEN DEFICIENCY AND BONE LOSS — The central role of estrogen deficiency in the pathogenesis of osteoporosis in postmenopausal women has been recognized for many years. Estrogen inhibits bone resorption and, after menopause, estrogen deficiency results in increased bone resorption and rapid bone loss. The mechanisms by which estrogen regulates bone remodeling are not fully established. However, estrogen is thought to affect osteoclastogenesis and osteoclast function through its effects on local cytokines and growth factors (eg, produced by either bone cells or adjacent marrow cells). This topic is reviewed separately. (See "Pathogenesis of osteoporosis", section on 'Sex steroid deficiency'.)

AI-induced estrogen deficiency — Although the primary source of estrogen in premenopausal women is the ovaries, the primary source in postmenopausal women is the adrenal gland, where aromatase converts adrenal androgens to estrogens. Aromatase inhibitors prevent conversion of androgens to estrogens. In postmenopausal women, AIs cause relatively rapid decreases in circulating estrogen [4,5]. (See "Androgen production and therapy in women".)

The AIs are divided into steroidal inactivators (exemestane) and nonsteroidal inhibitors (letrozole, anastrozole). Exemestane is a steroidal analogue of androstenedione and binds irreversibly to aromatase [6,7]. Nonsteroidal inhibitors, like letrozole or anastrozole, bind reversibly to the heme group of the enzyme by way of a basic nitrogen atom. At clinical doses, these third-generation AIs are successful in inhibiting greater than 97 percent of aromatase activity in vivo [4,8,9]. The half-life of these compounds varies from 27 hours for exemestane to 48 hours for letrozole and anastrozole [7,10,11].

In vivo animal studies suggest that exemestane may be more bone sparing than letrozole, owing to its androgenic structure [12,13]. However, there are no human trials showing a differential effect of the individual AIs on bone. The MA-27 trial is a comparative trial of exemestane versus anastrozole as adjuvant therapy in postmenopausal women. It includes end points such as bone mineral density (BMD) and fractures. The results are likely to provide more conclusive information about the skeletal effects of the steroidal versus nonsteroidal AIs.

SKELETAL OUTCOMES — Breast cancer treatments, such as surgical oophorectomy, gonadotropin-releasing hormone (GnRH) agonists, chemotherapy that induces ovarian failure, and aromatase inhibitors (AIs), all decrease endogenous estrogens and cause bone loss and increase the risk of fractures [14-20]. The more sudden and severe the estrogen deprivation occurs, the greater the magnitude of bone loss [15,16,21,22]. Bone loss is most rapid in premenopausal women receiving both ovarian suppression therapy (GnRH agonist) and an AI.

Bone mineral density — In several of the AI trials, BMD and bone turnover markers were evaluated in a subset of women. BMD of the LS and total hip (TH) were significantly reduced in postmenopausal women receiving AIs versus tamoxifen or placebo [13,21,23-25].

As examples:

  • In a substudy of the five-year Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial (n = 108 evaluable women), postmenopausal women with breast cancer randomly assigned to anastrozole had greater bone loss at the LS and TH (6 and 7.2 percent, respectively) compared with those assigned to tamoxifen (increase of 2.8 and 0.74 percent, respectively) [21].
  • In a substudy (206 evaluable patients) of the Intergroup Exemestane Study (IES), in which postmenopausal women who had taken tamoxifen for two to three years were randomly assigned to switch to exemestane or continue tamoxifen, subjects who switched to exemestane experienced a greater decline in BMD at the LS (2.7 percent) and TH (1.4 percent) after six months compared with those who remained on tamoxifen (no change at either site) [23]. Bone loss slowed in the remaining 18 months of the study, declining an additional 1.0 and 0.8 percent at the LS and TH, respectively, in subjects assigned to exemestane.

In premenopausal women, in whom the primary source of estrogen is the ovaries, AIs alone are not effective. However, in combination with the gonadotropin releasing hormone (GnRH) agonist goserelin, AIs cause more bone loss than tamoxifen. In the Austrian Breast and Colorectal Cancer Study Group (ABCSG)-12 trial, premenopausal women were randomly assigned to tamoxifen plus goserelin versus anastrozole plus goserelin [14]. Half of each group received zoledronic acid (ZA). Significant bone loss occurred in the subset of patients who did not receive ZA (17.3 and 11.6 percent reductions in patients receiving anastrozole/goserelin and tamoxifen/goserelin, respectively).

Biochemical markers of bone turnover — In several of the trials described above, markers of bone resorption (urine n-telopeptide and serum C-telopeptide [CTX]) and formation (serum bone specific alkaline phosphatase [BALP], N-terminal propeptide of type 1 procollagen [P1NP]) were significantly increased with AI treatment [23,24,26]. In contrast, bone turnover markers remained constant [23] or decreased [26] with tamoxifen therapy. (See "Bone physiology and biochemical markers of bone turnover" and "Use of biochemical markers of bone turnover in osteoporosis".)

Fracture — In several of the AI trials, fracture data were reported (table 1) [23,27-32]. In a meta-analysis of seven trials comparing AIs to tamoxifen in postmenopausal women with early stage breast cancer, use of AIs significantly increased the risk of bone fractures (OR 1.47, 95% CI 1.34-1.61) [33]. The majority of the trials were not designed to explore fracture outcomes as primary events; therefore, fracture and other skeletal events were collected as adverse events as part of a long-term safety and tolerability assessment. With exception of the MA-17 trial, all adjuvant AI trials demonstrated a significant increase in the rate of overall fractures compared with tamoxifen.

The MA-17 trial examined the efficacy of letrozole versus placebo in postmenopausal women who had completed five years of tamoxifen therapy. Of 5149 women, 256 had a clinical fracture (5.3 percent of patients assigned to letrozole compared with 4.6 percent assigned to placebo) [31]. The MA-17 trial is a "switch" trial, in which trial participants previously received five years of tamoxifen therapy. As tamoxifen mitigates bone loss in postmenopausal women [34], it may have contributed to decreasing the fracture rates in the AI treatment arm. The IES and combined ABCSG8/ARNO trials are also "switch" trials, but the duration of tamoxifen treatment (two to three years) was shorter than in the MA-17 trial, which could account for the difference in the findings.

In the ATAC trial comparing anastrozole with tamoxifen described above, the annual incidence of fractures was higher in women receiving anastrozole (11 versus 7.7 percent) throughout the five years of treatment [35]. However, beginning in the sixth year, the fracture rate decreased in the women previously assigned to anastrozole treatment such that in years seven to nine the fracture rates with both treatments were similar [30]. This suggests that AI-related fracture rates will decrease upon cessation of the drug.

EVALUATION

Assessment of fracture risk — Because AIs are associated with bone loss and fracture, women who will be initiating AIs require fracture risk assessment. Many studies have demonstrated that low BMD is associated with an increased risk of fracture. However, there are several clinical risk factors for fracture that are independent of BMD, such as advancing age, prior history of fragility fracture, chronic glucocorticoid use, low BMI, parental history of hip fracture, cigarette smoking, and excess alcohol. Thus, fracture risk assessment should include evaluation of the following:

  • Clinical risk factors for osteoporosis
  • Bone mineral density (BMD) measured by dual energy x-ray absorptiometry (DXA)

Osteoporosis risk factor assessment is reviewed in detail separately. (See "Osteoporotic fracture risk assessment", section on 'Dual-energy x-ray absorptiometry (DXA)' and "Osteoporotic fracture risk assessment", section on 'Skeletal site to measure' and "Osteoporotic fracture risk assessment", section on 'Clinical risk factor assessment'.)

We typically perform a history and physical examination to elicit clinical risk factors for fracture and lifestyle factors that contribute to bone loss, including smoking, excessive alcohol, physical inactivity, and poor nutrition (table 2). We obtain a bone mineral density study (DXA LS and hip) in women who will be starting AIs.

Several groups have published recommendations for the evaluation of fracture risk in women initiating AIs. These guidelines for evaluating bone density were developed largely from guidelines for screening, monitoring, prevention, and treatment of osteoporosis in postmenopausal women [36-39].

  • The American Society of Clinical Oncology (ASCO) recommends BMD testing (DXA) for postmenopausal women taking AIs and for premenopausal women who develop treatment-related premature menopause following treatment (table 3) [40].
  • The Belgian Bone Club recommends measuring BMD (DXA) and assessing risk factors for fracture in all women starting AIs or medical castration therapy [41].
  • A consensus statement from a UK Expert Group recommends measuring BMD (DXA) within three to six months of commencing AIs in all women except for those ≥75 years of age, in whom the decision to treat can be based upon age and clinical risk factor assessment, independent BMD [42]. (See 'Candidates for pharmacologic therapy' below.)

A survey of clinicians in the United Kingdom regarding practice patterns in treatment-induced bone loss in women with breast cancer revealed that a majority of them were not monitoring BMD in women receiving AIs, nor had confidence in their interpretation of DXA scans and knowing when to recommend treatment with bisphosphonates [43]. This survey suggests that more work is needed to educate clinicians about these issues.

Laboratory evaluation — Women initiating or already taking AIs may have risk factors for low bone mass other than estrogen deficiency. In a retrospective study of women (64 with breast cancer) referred to a bone health clinic during a six-year interval, 78 percent of the women with breast cancer had at least one secondary cause of bone loss, other than cancer or cancer-related therapies [44]. The most common finding was vitamin D insufficiency (38 percent with vitamin D <30 ng/mL [74.9 nmol/L]). Other causes of bone loss included idiopathic hypercalciuria and normocalcemic hyperparathyroidism.

In women who have low bone mass, laboratory evaluation may help identify other causes of osteoporosis such as renal or liver disease, hyperthyroidism, and hyperparathyroidism (table 4).

Women with low bone mass (T-score below -2.5) who are initiating or already taking AIs should have the following basic tests:

  • Biochemistry profile (especially calcium, phosphorous, albumin, total protein, creatinine, liver enzymes including alkaline phosphatase, electrolytes)
  • 25-hydroxyvitamin D
  • Complete blood count

Measuring urinary calcium excretion (24-hour collection) may identify women with idiopathic hypercalciuria. However, patients often find it inconvenient to collect a 24-hour urine specimen.

Women who have abnormalities on the initial laboratory testing or who have suspicious findings on history and physical examination may also require additional laboratory tests (table 5). The evaluation of osteoporosis is reviewed in detail separately. (See "Diagnosis and evaluation of osteoporosis in postmenopausal women", section on 'Evaluation'.)

PREVENTION AND TREATMENT OF AI-INDUCED BONE LOSS

Nonpharmacologic — We encourage all women to adopt lifestyle changes that promote not only bone health but overall health as well. These include increasing physical activity (including weight bearing exercise), reducing or stopping smoking, and taking calcium and vitamin D supplements [45-47]. (See "Overview of the management of osteoporosis in postmenopausal women", section on 'Nonpharmacologic therapy'.)

Adequate calcium and vitamin D intake can result in positive calcium balance and a reduction in the rate of loss of bone. However, the effect upon fracture risk is less clear. (See "Calcium and vitamin D supplementation in osteoporosis", section on 'Efficacy'.)

Despite the uncertainty whether calcium and vitamin D supplementation prevents fractures, guidelines for cancer treatment-induced bone loss include supplementation with calcium and vitamin D [36,40,48]. We suggest 1200 mg of elemental calcium (total diet plus supplement) and 800 international units of vitamin D daily.

In women with low vitamin D levels (25-hydroxyvitamin D level <20 ng/mL), vitamin D supplementation should be provided prior to therapy with bisphosphonates. Administration of bisphosphonates in the setting of vitamin D deficiency increases the risk of hypocalcemia. (See "Treatment of vitamin D deficiency in adults", section on 'Vitamin D repletion' and "Bisphosphonates in the management of osteoporosis in postmenopausal women", section on 'Hypocalcemia'.)

Pharmacologic therapy — The pharmacologic agents available for the prevention of aromatase inhibitor (AI)-induced bone loss in postmenopausal women are bisphosphonates and denosumab. Bisphosphonates are specific inhibitors of osteoclast-mediated bone resorption [49]. They are considered first-line pharmacologic therapy for postmenopausal women with osteoporosis. Denosumab is a humanized monoclonal antibody against RANKL that reduces osteoclastogenesis. It has been shown to improve bone mineral density in postmenopausal women. (See "Overview of the management of osteoporosis in postmenopausal women".)

There are currently few other treatment options for AI-induced bone loss. Raloxifene, a selective estrogen receptor modulator like tamoxifen, should not be given to breast cancer patients. Although recombinant human parathyroid hormone (PTH) is available for the treatment of postmenopausal osteoporosis, it is generally not used in breast cancer patients with AI-induced bone loss. In animal studies, high doses of PTH caused osteogenic sarcoma. Because radiation is a risk factor for the development of osteogenic sarcoma, PTH is contraindicated in patients who have had radiation therapy, which may prohibit its use in many patients with breast cancer. (See "Parathyroid hormone therapy for osteoporosis".)

There are no randomized trials comparing bisphosphonates to denosumab for the prevention of bone loss and fracture in women taking aromatase inhibitors. We favor bisphosphonates over denosumab as initial therapy because of their efficacy, favorable cost, and the availability of long-term safety data. For patients who are intolerant of or unresponsive to oral or intravenous bisphosphonates, denosumab is an alternative option. (See 'Candidates for pharmacologic therapy' below.)

Bisphosphonates

Efficacy — In several randomized trials, bisphosphonates prevented or reduced bone loss in women receiving AIs [50-55]. None of the trials were designed or powered to assess fractures as a primary outcome. Fracture data were collected as adverse events. In a meta-analysis of six trials evaluating bisphosphonates in women with breast cancer receiving AIs, bisphosphonates did not significantly decrease the number of fractures compared with placebo or no treatment (OR 0.79, 95% CI 0.53-1.17) [56]. The wide confidence interval suggests that the estimate of the treatment effect is imprecise, likely due to the low number of fractures in both groups. These trials were not designed to study fracture reduction specifically in women at highest risk for fracture.

The two largest randomized trials were the Zometa-Femara Adjuvant Synergy Trials (Z-FAST and ZO-FAST) [50-52]. In both trials, zoledronic acid (4 mg every six months) was evaluated for prevention of AI-induced bone loss. Postmenopausal women with estrogen receptor-positive early-stage breast cancer who were receiving adjuvant letrozole were randomly assigned to immediate treatment with ZA for five years or to delayed administration (when spine or hip T-score decreased to <-2.0 or the occurrence of fracture) [50]. All patients received 500 mg of calcium and 400 to 800 international units of vitamin D.

Results, thus far, are as follows (table 6):

  • By month 12, only 8 to 10 percent of the subjects who did not receive ZA at the outset had a fall in T-score to <-2.0 and received ZA, and no subjects with normal BMD at baseline developed osteoporosis.

    LS and TH BMD were better in the immediate treatment group. The differences between the immediate and delayed treatment groups in LS and TH BMD were 5.7 and 3.6 percent, respectively, in ZO-FAST and 4.4 and 3.3 percent, respectively, in Z-FAST [50,51].

    There was no difference in the incidence of fractures (1.0 to 2.0 percent) between groups in either study. Fractures were recorded as adverse events.
  • After 36 months of follow-up in the Z-FAST trial, between group differences in LS and TH BMD were 6.7 and 5.2 percent, respectively [57]. At this time point, 15 percent of women in the delayed group required ZA for a T-score decrease to <-2.0. There was no difference in the incidence of fractures between the two groups (5.7 versus 6.3 percent).

    After 36 months of follow-up in the ZO-FAST trial, between group differences in LS and TH BMD were 9.3 and 5.4 percent, respectively [58]. At this time point, 21 percent of women in the delayed group required ZA for a T-score decrease to <-2.0. There was no difference in the incidence of fractures between the two groups (5.0 versus 6.0 percent).

The SABRE trial was designed to evaluate the effect of weekly oral risedronate on bone loss in postmenopausal women receiving anastrozole [53]. In the SABRE trial, postmenopausal women receiving anastrozole were stratified by their baseline T-scores into low risk (T-score of ≥-1.0), moderate-risk (T-score between -1.0 and -2.0), and high risk (T-score <-2). The women with moderate risk were randomized in a double-blind fashion to receive oral risedronate 35 mg/week or placebo, whereas women at low risk received anastrozole alone and women at high-risk received anastrozole and risedronate [53]. After 24 months, there was a significant difference in the change in LS and TH BMD from baseline in moderate risk women, favoring risedronate (2.2 versus -1.8 percent and 1.8 versus -1.1 percent, respectively) (table 6). LS and TH BMD increased significantly (2 to 3 percent) in women in the high risk group and LS decreased significantly (-2.1 percent) in the low risk group.

Choice of bisphosphonate and dosing — There are currently insufficient data to determine relative efficacy of the individual bisphosphonates. In the Z- and ZO-FAST trials, ZA (4 mg) was administered intravenously every six months for five years [50,51]. However, other bisphosphonates and other schedules may be equally effective. In small trials in postmenopausal women with breast cancer taking AIs, oral risedronate and ibandronate were effective in reducing bone loss [54,55]. In these trials, bisphosphonates were administered using the same dose and schedule as those used for postmenopausal osteoporosis (without breast cancer). In healthy postmenopausal women with osteoporosis, ZA (5 mg) administered intravenously once yearly has been shown to prevent fracture. (See "Bisphosphonates in the management of osteoporosis in postmenopausal women", section on 'Zoledronic acid'.)

Thus, until additional data are available, choice of bisphosphonate depends upon patient preferences and potential cost issues. We favor weekly oral risedronate or alendronate as initial therapy. However, ZA is an option if the patient does not tolerate an oral bisphosphonate. Although there are currently no published randomized trials using an annual dose of ZA (5 mg) for women on AIs, this is also a reasonable dosing option. (See "Bisphosphonates in the management of osteoporosis in postmenopausal women", section on 'Choice of bisphosphonate'.)

Adverse effects — Prolonged therapy with bisphosphonates is generally well tolerated. However, patients should be periodically monitored for a number of complications, including renal insufficiency, hypocalcemia, and osteonecrosis of the jaw. (See "Risks of therapy with bone modifying agents in patients with advanced malignancy" and "Bisphosphonates in the management of osteoporosis in postmenopausal women", section on 'Adverse effects'.)

Osteonecrosis of the jaw is an emerging problem that seems dependent upon the dose and duration of bisphosphonate treatment. Osteonecrosis of the jaw is reviewed separately. (See "Bisphosphonates in the management of osteoporosis in postmenopausal women", section on 'Osteonecrosis of the jaw' and "Risks of therapy with bone modifying agents in patients with advanced malignancy", section on 'Osteonecrosis of the jaw'.)

In Z-FAST, women who were randomized to receive immediate ZA experienced more bone pain (11 to 12 percent versus 4 to 7 percent) and fevers (15 percent versus <1 percent), temporally associated with the ZA infusions, than women in the delayed ZA group. No moderate or severe renal dysfunction was observed. In the Z and ZO-FAST trials [50,51,57] and the Austrian Breast and Colorectal Cancer Study Group trial [14], there are currently no confirmed cases of jaw osteonecrosis in women receiving ZA every six months.

Denosumab — RANKL, a member of the tumor necrosis factor (TNF) superfamily of ligands and receptors, is essential for the function of bone-resorbing osteoclasts; RANKL accelerates osteoclastogenesis when it binds to its receptor, RANK, but is blocked by osteoprotegerin, which is produced by osteoblasts. Denosumab is a humanized monoclonal antibody against RANKL that reduces osteoclastogenesis. It has been shown to improve bone mineral density in postmenopausal women. (See "Denosumab for osteoporosis".)

In a two-year randomized trial of denosumab (60 mg subcutaneously every six months) versus placebo in 250 postmenopausal osteopenic (mean T-scores -0.88 to -1.33) women receiving adjuvant AI therapy, subjects in the denosumab group had significant increases in lumbar spine, total hip, and femoral neck BMD compared with placebo (between group differences of 7.6, 4.7, and 3.6 percent, respectively) [59]. There were no vertebral fractures and nonvertebral fractures occurred in eight subjects in each group. The most common side effects included arthralgia, back pain, and fatigue.

Denosumab for the treatment of bone loss associated with prostate cancer and for skeletal metastases is reviewed separately. (See "Managing the side effects of androgen deprivation therapy", section on 'Denosumab' and "Mechanisms of bone metastases", section on 'Osteoclasts'.)

Candidates for pharmacologic therapy — Data from some clinical trials suggest that zoledronic acid (added to anti-estrogen treatment with GnRH agonist goserelin and either tamoxifen or AI) improves disease-free survival. (See "Overview of the use of osteoclast inhibitors in early breast cancer", section on 'Prevention of breast cancer recurrence'.) Results from additional large trials in early stage breast cancer addressing the benefit of bisphosphonates (in addition to adjuvant chemotherapy, anti-estrogen therapy, or both) to reduce the risks of systemic recurrences are needed before bisphosphonates should be a standard component of adjuvant systemic therapy. This topic deals with administration of pharmacologic therapy when no decision to administer for breast cancer effect has been made.

The trials described above evaluate two different approaches to osteoporosis prevention. In the Z- and ZO-FAST and denosumab trials, pharmacologic therapy was administered to all subjects in the immediate treatment arm, irrespective of the baseline T-score. The SABRE trial used risk stratification and treatment was based upon a low T-score. In the three-year report from the Z-FAST trial, only 15 percent of subjects in the delayed treatment arm met criteria for receiving zoledronic acid (ZA), suggesting that treatment of all women regardless of BMD results is unnecessary. Choosing candidates for bisphosphonate therapy based upon a combination of BMD and clinical risk factors to quantify fracture probability is a more clinically relevant approach and represents a model for subsequent trials.

For the prevention of fracture in patients taking AIs, we suggest pharmacologic therapy in patients at high risk for fracture, including patients with osteoporosis (T-score <-2.5 or history of fragility fracture) and patients with T-scores between -1.0 and -2.5 who have risks for fracture other than AI therapy (table 2). (See "Osteoporotic fracture risk assessment", section on 'Clinical risk factor assessment' and "Diagnosis and evaluation of osteoporosis in postmenopausal women", section on 'T-score'.)

We favor weekly oral risedronate or alendronate as initial therapy. Intravenous zoledronic acid is an option if the patient does not tolerate an oral bisphosphonate. For patients who are intolerant of or unresponsive to oral or intravenous bisphosphonates, denosumab is an alternative option.

Guidelines from societies and expert groups are as follows:

  • Current ASCO guidelines suggest pharmacologic therapy in those with a BMD T-score ≤-2.5. In patients with BMD T-scores above -2.5, annual BMD testing is recommended with initiation of bisphosphonates when BMD T-score falls to <-2.5 [40]. The guidelines are currently being updated and the recommendations for annual DXA scans and threshold for treatment based on T-scores may change.
  • The UK Expert Group recommends bisphosphonate therapy for elderly women (>75 years) who have one or more risk factors for osteoporotic fracture, regardless of BMD [42]. In addition, they recommend bisphosphonates for postmenopausal women <75 years of age with T-scores <-2.0 or if bone loss in women with pre-existing osteopenia (T-score between -1.0 and -2.0) occurs at a rate ≥ to 4 percent per year.

    Due to the rapid bone loss that occurs in premenopausal women receiving ovarian suppression with a GnRH agonist and AI, they recommend bisphosphonates for such women if the T-score is ≤-1.0.

    In women who are not candidates for bisphosphonates initially, they recommend repeat DXA after 24 months and initiation of bisphosphonates when the above criteria are met.
  • The Belgian Bone Club recommends bisphosphonates for patients with a T-score <-2.5 or history of fragility fracture. In addition, they recommend treatment for patients with T-scores between -1.0 and -2.5 in the presence of risk factors (other than AIs). In patients not prescribed bisphosphonates, regular measurement of BMD is necessary. Bisphosphonates should be initiated if significant bone loss occurs.

Monitoring response to therapy — Monitoring the response to therapy is important for identifying patients who are not responding. While there are a number of approaches to monitoring therapy, there is no consensus on the optimal approach. (See "Overview of the management of osteoporosis in postmenopausal women", section on 'Monitoring the response to therapy'.)

Our approach is to measure BMD two years after initiation of therapy and every two years or less frequently thereafter. BMD that is stable or improving is evidence for a treatment response. The finding of a clinically significant BMD decrease in a treated patient should trigger additional evaluation for contributing factors that may include poor adherence to therapy, inadequate gastrointestinal absorption, inadequate intake of calcium and vitamin D, or the development of a disease or disorder with adverse skeletal effects.

SUMMARY AND RECOMMENDATIONS

Evaluation

  • In patients initiating AIs, we suggest DXA of the hip and lumbar spine. (See 'Evaluation' above.)
  • Patients initiating AIs should also be assessed for other clinical risk factors for osteoporosis. The most robust non-BMD risk factors are age and prevalent fracture. Others are long-term glucocorticoid therapy, parental history of hip fracture, cigarette smoking, and excess alcohol intake (table 2). (See 'Evaluation' above.)

Management

Lifestyle

  • We encourage all women to adopt lifestyle changes that promote not only bone health but overall health as well. These include increasing physical activity (including weight bearing exercise), reducing or stopping smoking, and taking calcium and vitamin D supplements (1200 mg of elemental calcium (total diet plus supplement) and 800 international units of vitamin D daily are suggested). (See 'Nonpharmacologic' above.)

Pharmacologic — Not all women receiving AIs require treatment with pharmacologic therapy. Risk stratification based upon baseline BMD T-scores and clinical risk factors can identify who is more or less likely to benefit from bisphosphonates.

  • For women initiating AIs who have a BMD T-score ≤-2.5 or history of a fragility fracture, we recommend pharmacologic treatment (Grade 1A). We also suggest treatment for women with a BMD T-score between -1.0 and -2.5 who have risks for fracture other than AI therapy (table 2) (Grade 2B). (See 'Candidates for pharmacologic therapy' above.)
  • In patients who do not meet the above criteria, we typically measure BMD (DXA) every two years and prescribe pharmacologic therapy as indicated above.
  • For the prevention of bone loss and fracture, we suggest bisphosphonates as first-line therapy (Grade 2B). Denosumab is an alternative option for women who do not tolerate or are unresponsive to oral and intravenous bisphosphonates. (See 'Pharmacologic therapy' above and 'Bisphosphonates' above and 'Denosumab' above.)

The choice of bisphosphonate depends upon patient preference and cost. We favor weekly oral risedronate or alendronate as initial therapy. However, zoledronic acid is an option if the patient does not tolerate oral bisphosphonates. The optimal schedule and duration of ZA has not been defined for AI-induced bone loss. Four mg every six months or 5 mg annually are reasonable dosing options. (See 'Choice of bisphosphonate and dosing' above.)

Monitoring — There is no consensus on the optimal strategy for monitoring patients on therapy. However, we typically measure BMD every two years after initiation of pharmacologic therapy. (See 'Monitoring response to therapy' above.)

Use of UpToDate is subject to the Subscription and License Agreement.

REFERENCES

  1. Brueggemeier RW. Aromatase, aromatase inhibitors, and breast cancer. Am J Ther 2001; 8:333.
  2. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348:2431.
  3. Confavreux CB, Fontana A, Guastalla JP, et al. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 2007; 41:346.
  4. Geisler J, Lønning PE. Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations. J Steroid Biochem Mol Biol 2005; 95:75.
  5. Simpson ER, Dowsett M. Aromatase and its inhibitors: significance for breast cancer therapy. Recent Prog Horm Res 2002; 57:317.
  6. Dixon JM. Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment. Expert Rev Anticancer Ther 2002; 2:267.
  7. Lønning PE. Pharmacology and clinical experience with exemestane. Expert Opin Investig Drugs 2000; 9:1897.
  8. Geisler J. Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. J Steroid Biochem Mol Biol 2003; 86:245.
  9. Geisler J, Haynes B, Anker G, et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002; 20:751.
  10. Lamb HM, Adkins JC. Letrozole. A review of its use in postmenopausal women with advanced breast cancer. Drugs 1998; 56:1125.
  11. Wiseman LR, Adkins JC. Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer. Drugs Aging 1998; 13:321.
  12. Goss PE, Qi S, Josse RG, et al. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 2004; 34:384.
  13. Lønning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005; 23:5126.
  14. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007; 25:820.
  15. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001; 19:3306.
  16. Saarto T, Blomqvist C, Välimäki M, et al. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 1997; 15:1341.
  17. McCloskey E. Effects of third-generation aromatase inhibitors on bone. Eur J Cancer 2006; 42:1044.
  18. Perez EA. Safety of aromatase inhibitors in the adjuvant setting. Breast Cancer Res Treat 2007; 105 Suppl 1:75.
  19. Eastell R. Aromatase inhibitors and bone. J Steroid Biochem Mol Biol 2007; 106:157.
  20. Saad F, Adachi JD, Brown JP, et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 2008; 26:5465.
  21. Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008; 26:1051.
  22. Warming L, Hassager C, Christiansen C. Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporos Int 2002; 13:105.
  23. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007; 8:119.
  24. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006; 24:3629.
  25. Hadji P, Ziller M, Kieback DG, et al. Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy. Ann Oncol 2009; 20:1203.
  26. Eastell R, Hannon RA, Cuzick J, et al. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006; 21:1215.
  27. Coates AS, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25:486.
  28. Rabaglio M, Sun Z, Price KN, et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009; 20:1489.
  29. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369:559.
  30. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9:45.
  31. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97:1262.
  32. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366:455.
  33. Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2011; 103:1299.
  34. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326:852.
  35. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60.
  36. Khan AA, Brown JP, Kendler DL, et al. The 2002 Canadian bone densitometry recommendations: take-home messages. CMAJ 2002; 167:1141.
  37. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359:1929.
  38. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008; 19:399.
  39. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285:785.
  40. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21:4042.
  41. Body JJ, Bergmann P, Boonen S, et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club. Osteoporos Int 2007; 18:1439.
  42. Reid DM, Doughty J, Eastell R, et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008; 34 Suppl 1:S3.
  43. Lester JE, Dodwell D, Horsman JM, et al. Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom. Br J Cancer 2006; 94:30.
  44. Camacho PM, Dayal AS, Diaz JL, et al. Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis. J Clin Oncol 2008; 26:5380.
  45. Schwartz AL, Winters-Stone K, Gallucci B. Exercise effects on bone mineral density in women with breast cancer receiving adjuvant chemotherapy. Oncol Nurs Forum 2007; 34:627.
  46. Demark-Wahnefried W, Aziz NM, Rowland JH, Pinto BM. Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol 2005; 23:5814.
  47. Demark-Wahnefried W, Pinto BM, Gritz ER. Promoting health and physical function among cancer survivors: potential for prevention and questions that remain. J Clin Oncol 2006; 24:5125.
  48. Michaud LB, Goodin S. Cancer-treatment-induced bone loss, part 2. Am J Health Syst Pharm 2006; 63:534.
  49. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19:733.
  50. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007; 25:829.
  51. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 2008; 112:1001.
  52. Aapro M. Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program. Breast 2006; 15 Suppl 1:S30.
  53. Van Poznak C, Hannon RA, Mackey JR, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010; 28:967.
  54. Lester JE, Dodwell D, Purohit OP, et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008; 14:6336.
  55. Greenspan SL, Brufsky A, Lembersky BC, et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 2008; 26:2644.
  56. Valachis A, Polyzos NP, Georgoulias V, et al. Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: a meta-analysis. Gynecol Oncol 2010; 117:139.
  57. Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009; 9:77.
  58. Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010; 21:2188.
  59. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26:4875.
Topic 2062 Version 5.0

TOPIC OUTLINE

GRAPHICS

RELATED TOPICS

All topics are updated as new information becomes available. Our peer review process typically takes one to six weeks depending on the issue.